Connie Hsu

Connie Hsu

Auto-generated profile, based on publicly available information

Connie Hsu

Department of Physical Medicine and Rehabilitation Spaulding Rehabilitation Hospital Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2022 in Physical Medicine and Rehabilitation Clinics of North America
Verified
Journal Article
Closed access
CHConnie Hsu
Connie Hsu
KVKevin Vu
Kevin Vu
JBJoanne Borg-Stein
Joanne Borg-Stein

7 October 2024 in Allergy
Verified
Journal Article
Open access
ARAvner Reshef
Avner Reshef
CHConnie Hsu
Connie Hsu
CKConstance H. Katelaris
Constance H. Katelaris
Philip LiPhilip Li
Philip Li
MMMarkus Magerl
Markus Magerl
TGthe VANGUARD Study Group
the VANGUARD Study Group
Background: Hereditary angioedema (HAE) is a chronic, unpredictable disease. Long‐term prophylactic treatments that offer durable efficacy, safety, and convenience are required to assist patients in achieving complete disease control, per international guidelines. We report an interim analysis of an ongoing phase 3 (VANGUARD) open‐label extension (OLE) study evaluating the long‐term safety and efficacy of garadacimab for HAE prophylaxis.Methods: Adults and adolescents aged ≥12 years with HAE previously participating in phase 2 and pivotal phase 3 (VANGUARD) studies were rolled over to an OLE, alongside newly enrolled patients. Patients received garadacimab 200 mg subcutaneously, once monthly for ≥12 months. The primary endpoint was treatment‐emergent adverse events (TEAEs) in patients with C1 inhibitor deficiency/dysfunction.Results: At data cut‐off (February 13, 2023; N = 161), median (interquartile range) exposure was 13.8 months (11.9–16.3). For the primary endpoint, 133/159 patients experienced ≥1 TEAE (524 events), equivalent to 0.23 events/administration and 2.84 events/patient‐year. Garadacimab‐related TEAEs (13% of patients, 52 events) were most commonly injection‐site reactions (ISRs). No deaths occurred. One patient discontinued treatment due to garadacimab‐related moderate ISR. Most TEAEs were mild/moderate; three events were serious (COVID‐19, two events; abdominal HAE attack, one event) and not garadacimab related. No abnormal bleeding, thromboembolic, severe hypersensitivity, or anaphylactic events were observed. Mean HAE attack rate decreased by 95% from the run‐in period; 60% of patients were attack‐free. Almost all patients (93%) rated their response to garadacimab as “good” or “excellent.”Conclusion: Garadacimab has a favorable safety profile suitable for long‐term use and provides durable protection against HAE attacks.

1 June 2024 in PM&R
Verified
Journal Article
Closed access
CHConnie Hsu
Connie Hsu
TAToqa Afifi
Toqa Afifi
ZIZacharia Isaac
Zacharia Isaac

19 March 2024 in PM&R
Verified
Journal Article
Closed access
PDF file
CHConnie Hsu
Connie Hsu
TGTimothy Genovese
Timothy Genovese
KMKelly C. McInnis
Kelly C. McInnis


16 May 2023 in PM&R
Verified
Journal Article
Closed access
CHConnie Hsu
Connie Hsu
BLBryan Le
Bryan Le
ABAshwin Babu
Ashwin Babu
Adam S. TenfordeAdam S. Tenforde
Adam S. Tenforde